|Bid Price||-||Offer Price||-|
|Mid Price||GBX 1,044.00||Day Change||GBX -9.00 (-0.85%)|
|Price Date||24 Nov 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.00 %|
|Total Expense Ratio||0.77||Fund Size||315,596,000.00|
|Launch Date||03/05/2011||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||0.75||Sector||IMA UK Equity Income|
|Min Investment (£)||1,000.00||Total Expense Ratio (%)||0.77|
|ISIN||GB0006059223||Min TopUp (£)||0.00|
The objective is to produce attractive returns over the long term by investing globally in transferable securities of companies that the ACD considers offer excellent future growth prospects. The Fund may also invest in money market instruments, cash and near cash. In addition, the Fund also has the ability to invest up to (but no more than) 10% in value of the Fund in each of the following: collective investment schemes and deposits.
Douglas graduated BSc in Molecular Biology & Biochemistry from Durham University in 1997 and with a DPhil in Molecular Immunology from Oxford University in 2001. He joined Baillie Gifford in 2001 and is Head of the Global Discovery Team. Douglas became a Partner in 2015 and is a CFA Charterholder.